Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
SanBio Co ( (JP:4592) ) has shared an update.
SanBio Co., Ltd. announced that the Ministry of Health, Labour and Welfare in Japan has approved a partial change to the marketing authorization for AKUUGO, a regenerative therapy for brain injuries. This change lifts certain shipment restrictions, allowing the company to proceed with its plans to launch the product following its NHI price listing. The company aims to expand its operations in the U.S. market with a Phase 3 clinical trial for traumatic brain injury and plans to discuss clinical trials for a stroke program in Japan, positioning itself as a leader in regenerative medicine.
The most recent analyst rating on (JP:4592) stock is a Sell with a Yen1010.00 price target. To see the full list of analyst forecasts on SanBio Co stock, see the JP:4592 Stock Forecast page.
More about SanBio Co
SanBio Co., Ltd. operates in the regenerative medicine industry, focusing on developing innovative therapies for neurological conditions. Its primary product, AKUUGO, is a pioneering regenerative therapy for the brain, targeting chronic motor paralysis due to traumatic brain injury.
Average Trading Volume: 2,699,435
Technical Sentiment Signal: Sell
Current Market Cap: Yen136.2B
Find detailed analytics on 4592 stock on TipRanks’ Stock Analysis page.